All Blogs

Aug 19, 2014

The “ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides in...

Aug 18, 2014

DelveInsight’s,“ Brain Hemorrhage-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Brain Hemorrhage. This report provides information on the therapeu...

Aug 14, 2014

DelveInsight’s, “ Rheumatoid Arthritis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufactu...

Aug 08, 2014

Over the past six months, DelveInsight has proven its value to their customers with its excellent deliverables. Now newly launched DelveInsight's Pipeline Reports is the answer to all looking for top notch drug development information. In the fast-paced, competitive field of clinical research, organizations must...

Aug 01, 2014

“If a market is growing enormously, you need to understand what’s nourishing it” DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights. Pharm Delve reports are known for its extensive detailed information of the Marketed drugs- Global Market, API Market & Manufacturer...

Jul 25, 2014

The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...

Jul 24, 2014

Get the idea what Other Companies are doing with the Targets you are Interested In and what their progress and strategize to get the best out of it with our MOA Pipeline Reports. After a successful launch of Drug and Indication Reports under Pharm Delve Series, DelveInsight has come up with a Pipeline Reports under ...

Jul 18, 2014

Compare the global sales of 2013 and 2012 of the top ten blockbuster drugs which is losing patent this year. Teva Pharmaceutical's Copaxone is the most affected drugs in terms of sales as the sales of 2013 has increased to 4.328 billions bearing the highest loss. Least affected Drug is AbbVie's Trilipix which has f...

Jul 18, 2014

On May 30, 2014, the U.S. Food and Drug Administration approved the first generic versions of Celebrex (celecoxib) capsules. Teva Pharmaceutical Industries received approval to market celecoxib capsules in 50 milligram, 100 mg, 200 mg, and 400 mg strengths, and has 180-day exclusivity on the 100 mg, 200 mg, and 400 ...

Jul 03, 2014

We DELVEINSIGHT are Business Consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. Our company can provide valuable insight across all Pharmaceutical industries which include Drug Manufacturing to API Manufacturers&nb...